Golay, J., Ubiali, G., & Introna, M. (2017). The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica.
Chicago-tyylinen lähdeviittausGolay, Josée, Greta Ubiali, ja Martino Introna. "The Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity against Chronic Lymphocytic Leukemia B Cells With CD20 Antibodies." Haematologica 2017.
MLA-viiteGolay, Josée, Greta Ubiali, ja Martino Introna. "The Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity against Chronic Lymphocytic Leukemia B Cells With CD20 Antibodies." Haematologica 2017.